Use of crizotinib as neoadjuvant therapy for non‐small cell lung cancers patient with ROS1 rearrangement: A case report-Reference-Cited by-同舟云学术

Use of crizotinib as neoadjuvant therapy for non‐small cell lung cancers patient with ROS1 rearrangement: A case report

Published:2021-08-17 Issue:20 Volume:12 Page:2815-2818
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Zhao Shikang¹²,Zhu Shuai¹²,Lei Xi¹²,Xu Dongbo³,Shi Tao⁴,Chen Qiusong⁵,Ren Fan¹,Chen Gang¹,Huang Dingzhi⁶^ORCID,Xu Song¹²^ORCID

Affiliation:

1. Department of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin China

2. Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment Lung Cancer Institute, Tianjin Medical University General Hospital Tianjin China

3. Department of Pathology Tianjin Medical University General Hospital Tianjin China

4. Precision Medicine Center Tianjin Medical University General Hospital Tianjin China

5. Department of PET/CT Diagnostic Tianjin Medical University General Hospital Tianjin China

6. Department of Thoracic Oncology Tianjin Medical University Cancer Institute and Hospital Tianjin China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14112

Reference6 articles.

1. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors

2. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

3. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

4. Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC

5. The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer;World Journal of Surgical Oncology;2024-06-18

2. “Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”;Diagnostic Pathology;2023-05-27

3. Crizotinib;Reactions Weekly;2022-10-29

4. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review;Frontiers in Oncology;2022-10-27

5. Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report;Frontiers in Oncology;2022-08-16